A Phase I Dose-Escalation Study of the Selective PKC- Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor: |
MindSight Pharmaceuticals, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR9532 |
U.S. Govt. ID: |
NCT03492125 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
MS-553 is being tested for its potential to block a specific enzyme (Protein Kinase C) that is known to play a role in the growth and survival of cancer cells in different types of leukemia. The purpose of this study is to determine the safety, recommended dose and preliminary activity of MS-553 in treating CLL/SLL.
This study is closed
Investigator
Nicole Lamanna, MD
Are you 18 years of age or older? |
Yes |
No |
Do you have CLL or SLL? |
Yes |
No |